文献速递血管炎

美国明尼苏达州奥姆斯特德县ANCA相关血管炎20年人群流行病学研究

The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota: A Twenty-Year US Population-Based Study.
PubMed 文献 · Arthritis Rheumatol · 2017-11-09

该研究回顾1996至2015年奥姆斯特德县成人ANCA相关血管炎(AAV)病历,估算年发病率、患病率和死亡率。58例 incident 病例中MPA占48%、GPA占40%、EGPA占12%;年发病率3.3/10万,患病率42.1/10万。MPA、EGPA及MPO-ANCA阳性患者死亡率高于明尼苏达州一般人群,而GPA、PR3-ANCA阳性及ANCA阴性患者死亡率无差异。

要点

  • AAV年发病率3.3/10万,患病率42.1/10万,高于全球其他地区报道。
  • MPA发病率与GPA相近,MPO-ANCA阳性占61%。
  • MPA、EGPA及MPO-ANCA阳性患者死亡率高于一般人群。

核心结论

  • 研究期间AAV年发病率为3.3/10万,患病率为42.1/10万,显著高于世界其他地区报道。
  • GPA发病率与MPA相似,MPA和EGPA患者死亡率高于明尼苏达州一般人群,GPA患者无差异。
  • MPO-ANCAs是该AAV人群中生存不良的标志。

研究设计与样本

  • 基于美国明尼苏达州奥姆斯特德县1996年1月1日至2015年12月31日所有疑似或确诊AAV患者病历的回顾性人群研究。
  • 共纳入58例incident AAV病例,发病率按2010年美国白人人口进行年龄和性别调整,患病率计算于2015年1月1日。
  • 研究队列观察生存率与明尼苏达州人群预期生存率进行比较。

主要发现

  • 58例incident AAV中GPA 23例(40%)、MPA 28例(48%)、EGPA 7例(12%)。
  • 28例(48%)为女性,57例(98%)为白人,诊断时平均年龄61.1±16.5岁。
  • AAV年发病率3.3/10万(95%CI 2.4-4.1);GPA 1.3/10万(95%CI 0.8-1.8),MPA 1.6/10万(95%CI 1.0-2.2),EGPA 0.4/10万(95%CI 0.1-0.6)。
  • AAV总体患病率42.1/10万(95%CI 29.6-54.6);AAV总体、EGPA、MPA及MPO-ANCA阳性患者死亡率高于明尼苏达州一般人群(各P<0.05),GPA、PR3-ANCA阳性及ANCA阴性患者死亡率与一般人群无差异。

临床怎么用

  • 该人群数据提示AAV疾病负担较高,临床需关注MPA、EGPA及MPO-ANCA阳性患者的生存预后。
  • GPA与MPA发病率相近,诊断分类时应结合ANCA血清型综合评估。

局限性

  • 研究基于单一县区人群,结果外推需谨慎。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the annual incidence, prevalence, and mortality of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) and its subsets, granulomatosis with polyangiitis (Wegener's) (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA), in a US-based adult population. METHODS: All medical records of patients with a diagnosis of, or suspicion of having, AAV in Olmsted County, Minnesota from January 1, 1996 to December 31, 2015 were reviewed. AAV incidence rates were age- and sex-adjusted to the 2010 US white population. Age- and sex-adjusted prevalence of AAV was calculated on January 1, 2015. Survival rates observed in the study cohort were compared with expected rates in the Minnesota population. RESULTS: Of the 58 incident cases of AAV in Olmsted County during the study period, 23 (40%) were cases of GPA, 28 (48%) were cases of MPA, and 7 (12%) were cases of EGPA. Overall, 28 (48%) of the patients with AAV were women and 57 (98%) were white. The mean ± SD age at diagnosis was 61.1 ± 16.5 years. Thirty-four patients (61%) had myeloperoxidase (MPO)-ANCAs, and 17 (30%) were positive for proteinase 3 (PR3)-ANCAs; 5 (9%) were ANCA-negative. The annual incidence of AAV was 3.3 per 100,000 population (95% confidence interval [95% CI] 2.4-4.1). The incidence rates of GPA, MPA, and EGPA were 1.3 (95% CI 0.8-1.8), 1.6 (95% CI 1.0-2.2), and 0.4 (95% CI 0.1-0.6), respectively. The overall prevalence of AAV was 42.1 per 100,000 (95% CI 29.6-54.6). The mortality rate among AAV patients overall, and among patients with EGPA, those with MPA, and those with MPO-ANCAs, was increased in comparison to the Minnesota general population (each P < 0.05), whereas mortality rates among patients with GPA, those with PR3-ANCAs, and ANCA-negative patients did not differ from that in the general population. CONCLUSION: The annual incidence of AAV in Olmsted County, Minnesota over the 20 years of the study was 3.3 per 100,000, with a prevalence of 42.1 per 100,000, which is substantially higher than the rates reported in other areas worldwide. The incidence of GPA was similar to that of MPA. Patients with MPA and those with EGPA, but not patients with GPA, experienced higher rates of mortality than that in the Minnesota general population. MPO-ANCAs were a marker of poor survival in this population of patients with AAV.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Berti A, Cornec D, Crowson CS, et al. The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota: A Twenty-Year US Population-Based Study. Arthritis Rheumatol. 2017. PMID: 28881446. doi:10.1002/art.40313

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。